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Purpose: The aim of this retrospective study is to present data on clinical significance of
lactate dehydrogenase (LDH) serum levels in an unselected contemporary patient population
with small cell lung cancer (SCLC) in limited disease (LD) and extensive disease stage (ED).
Patients and methods: From June 2004 to June 2008, our electronic database including all
in-patient and out-patient contacts was searched for patients with newly diagnosed LD and
ED SCLC. 397 cases were identified. We collected data on patient characteristics including
clinical performance status and LDH serum levels, metastatic sites, efficacy of first line chemo-
therapy and survival.
Results: In both limited and extensive disease SCLC, elevated LDH serum levels resulted in
significantly shorter median survival. The effect was most pronounced if levels were 300 U/l
or higher. In patients with limited disease and normal LDH levels, median survival was
18.0 months. If LDH was higher than 300 U/l, overall survival was reduced to 12 months. In
cases with extensive disease, overall survival was significantly lower in patients with elevated
LDH serum levels with an additional reduction in overall survival in patients with LDH levels
above 300 U/l. (7.0 vs. 12.0 months, p Z <0.001). Multivariate Cox regression analyses re-
vealed LDH levels to be an independent predictor of mortality after adjustment for age and
Performance Status in LD and ED SCLC (HR 1.003, p Z 0.017; HR 1.001, p Z 0.002 respec-
tively). However, categorizing LDH levels revealed no significant difference in LD SCLC.
Conclusion: In our contemporary comprehensive patient population, LDH is proved to be
a strong, independent predictive factor of median survival in patients with LD and ED SCLC.
ª 2010 Elsevier Ltd. All rights reserved.02 6010; fax: þ49 4102 601343.
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Lung cancer is still the leading cause of death in patients
with cancer.1 It accounts for over 800 000 deaths worldwide
every year. The frequency of SCLC has been slightly
decreasing over the last 20 years. The prognosis of SCLC has
not changed much since the seventies, until the value of
prophylactic brain irradiation in treatment responders was
demonstrated.2 In extensive disease stage patients without
treatment, median survival is about 6e8 weeks after
establishment of diagnosis.3 With chemotherapy, median
survival reaches 9e11 months. In limited stage SCLC,
median survival without treatment is 15e17 weeks. With
combined radiochemotherapy, 22e27 months are achiev-
able. The most important prognostic factors in SCLC are
disease stage, clinical performance status (PS) and lactate
dehydrogenase (LDH).4 Pre-treatment serum levels of
albumin, neuron-specific enolase and carcinoembryonal
antigen are less useful in determining the course of the
disease but might be used as additional tools in a follow-up
setting.5e8
The significance of LDH had been examined for patients
with lymphoma, sarcoma and multiple myeloma.9e13 The
role of LDH as prognostic factor in SCLC has been estab-
lished in the last decades and was proven again.14e24 The
aim of our study was to examine the clinical importance of
pre-treatment LDH serum levels on overall survival in an
unselected patient population with LD and ED SCLC at our
institution.
Patients and methods
Our electronic database including all in-patient and out-
patient contacts was searched for patients with newly
diagnosed LD and ED SCLC from June 2004 to December
2008. We identified 397 patients.
All patients had SCLC confirmed by histology or
cytology. Previous chemotherapy, radiotherapy or surgery
was not performed before staging and evaluation of LDH
serum levels. Performance status ranged from 0 to 3 on
the Eastern Cooperative Oncology Group (ECOG) scale.
There were 4 patients with other malignancies in the past,
all of these patients had normal LDH serum levels. At base
line, no patient suffered of acute heart failure, acute
coronary syndrome or severe hepatic dysfunction. Renal
and hematologic parameters were normal. Thus, relevant
possible confounding factors for elevated LDH serum
levels were eliminated as far as possible in a clinical
setting.
All patients with newly diagnosed SCLC had a complete
history and physical examination taken. Performance status
was evaluated at base line. A staging procedure was per-
formed including bronchoscopy, CT-scan of the chest and
upper abdomen, CT-Scan or MRI of the brain, bone scan and
a comprehensive laboratory panel including hematologic,
renal and hepatic function tests and LDH. In patients with
clinical diagnosis of LD SCLC, a bone marrow specimen was
obtained by the method of Jamshidi. Serum levels of NSE or
other serum tumor markers were not routinely assessed.
LDH serum levels were available in 395 of 397 patients
(99.5%).Of each patient with SCLC, every single electronic report
was reviewed. We collected data on age, disease stage,
date of initial diagnosis, last observation and survival in
months, performance status, levels of lactate dehydroge-
nase, metastatic sites, and result of first line chemotherapy
(complete response, partial response, stable disease and
progressive disease).
The vast majority of responses were evaluated using
the RECIST criteria.25 Complete response (CR) is defined
as a complete disappearance of all target lesions.
Partial response (PR) means a decrease of the sum of
the greatest diameter of all target lesions of more than
30% compared with base line measurement. Stable
disease (SD) is present if target lesions do not vary in
size by more than 20%. Progression of disease was
the case in a greater than 20% increase of the above
named sum.
Survival time was measured from the date of diagnosis to
the date of death. There was a minimum delay between
diagnosis and start of chemotherapy ranging from 1 to
maximum 5 days.
LDH serum levels were assessed by UV-test. The cata-
lytic activity of LDH was determined by measurement of
increased absorbency of nicotineeadenine dinucleotide at
340 nm as a result of catalytic oxidation of lactate to
pyruvate. The normal reference range is 135e225 Units per
liter (U/l) at our hospital. All LDH measures were per-
formed at our hospitals’ clinical laboratory (COBAS Integra
700, Roche).
The method of Kaplan and Meier29 was used to calcu-
late survival curves. To assess the statistical significance of
differences between survival curves, we performed log-
rank tests. Multivariate testing was done by Cox regression
analyses. LDH was first categorized into two levels
(LDH <225 and LDH >225 U/l). Then we applied a three
level categorization with the lowest level as reference
(LDH <225, LDH 225e300 and LDH >300 U/l). An adjust-
ment was performed for age, disease stage (limited versus
extensive disease) and performance status (PS 0e1
versus 2e4).
Results
Limited disease
155 pts (39%) had limited disease at time of diagnosis. The
median age of patients with SCLC LD was 63 years (range
38e83). 138 pts (86%) were in ECOG performance status
0e1; 10 pts (10%) in PS 2 and 6 (4%) in PS 3.
LDH levels were available in all but one patient (99.4%).
Range was from 97 to 901 units per liter (U/l) with a median
level of 230 U/l. In 98 patients (63%) LDH was equal or
below 225 U/l which is the upper normal level at our
hospital. In 56 (36%) of the cases the level was higher than
225 U/l. In 25 patients (15%), highly elevated levels
(>300 U/l) were detected.
A relevant difference regarding Performance Status
(PS) was not seen comparing the cohorts with normal
vs. elevated LDH levels (1.10 vs. 1.18).
Equally, age showed no clinically relevant difference
(61 vs. 63 years).
Table 1 LDH serum levels and treatment response in
limited disease SCLC.
Response LDH <225 U/l
n Z 98
LDH >225 U/l
n Z 57
P-Value *
Complete response 12.2% 19.3% 0.234
Partial response 62.2% 59.6% 0.749
Response rate** 74.5% 78.9% 0.530
Stable disease 17.3% 12.3% 0.400
Progressive disease 8.2% 8.8% 0.895
*Chi-square test.
**Response rate: sum of complete and partial responses.
Table 3 Log-rank test for median survival in LD SCLC with
different LDH serum levels.
LDH level (U/l) Median Survival (months) p-value
LDH  225 18.0 (13.2e22.8) Ref.
LDH > 225e<300 17.0 (11.5e22.4) 0.206
LDH > 300 12.0 (9.0e14.9) 0.279
LDH in small cell lung cancer 1939In the 98 pts with normal LDH levels, partial response
(PR) was reached in 62.6% and complete response (CR) in
12.2%; thus yielding a response rate (RR) of 74.5%. 8.2%
had progressive disease (PD) after first line chemotherapy.
20 pts were still alive at time of data analysis. The
remaining 71 pts had a median survival of 20.0 months.
In the group with LDH levels higher than 225 U/l, 59.6%
had PR as result of first line chemotherapy, CR was ach-
ieved in 19.3% (RR: 78.9%). 8.8% were progressive. 11 pts
out of 55 were censored. The remaining 44 pts showed
a median survival of 14.5 months. There was no statistical
significant difference in treatment response between the
two LDH categories (Table 1).
Analysis of all cases with LD SCLC including censored
events (20%) showed a not statistically significant reduction
of median survival in patients with elevated LDH levels
compared to the cases with normal LDH levels (Table 2).
We then divided the cases with elevated LDH levels in
two groups (LDH 225e300 and LDH <300 U/l). Median
survival was markedly reduced in the group with LDH levels
above 300 U/l. Again, this difference was not statistically
significant (Table 3, Figs. 1 and 2).
However, multivariate Cox regression analyses revealed
LDH levels to be an independent predictor of mortality
after adjustment for age and Performance Status in LD
SCLC (Hazard Ratio 1.003, p Z 0.017) (Table 4).
Extensive disease
242 pts (61%) were in extensive disease stage. The median
age of patients with SCLC ED was 64 (range 41e81) years.
194 pts (80%) were in performance status 0e1; 37 (15%) in
PS 2 and 11 (5%) in PS 3. Main metastatic sites in all patients
with SCLC ED were: Liver (42%), brain (22%), bone (29%),
adrenal glands (16%) and pleura (16%).
LDH levels could be retrieved for 99.6% of all patients.
The median level was 317 U/l (range 99e3575).Table 2 Log-rank test for median survival in LD SCLC with
normal versus elevated LDH serum levels.
LDH level (U/l) Median Survival (months) p-value
LDH  225 18.0 (13.2e22.8) Ref.*
LDH > 225 14.0 (9.8e18.2) .138
*Reference.In 87 pts (36%), LDH was found to be lower or equal the
upper limit normal of 225 U/l. In 153 pts (64%), LDH was
higher than 225 U/l. Severe elevated levels (>300 U/l) were
seen in 84 patients (35%).
We performed an additional analysis of localization of
metastases and number of metastatic sites in patient group
with different LDH levels. We observed a considerably
higher frequency of liver metastasis (58 vs. 25%) and bone
metastasis (34 vs. 20%) in patients with severe elevated LDH
levels (>300 U/l) compared to the subset with normal LDH
levels. On the other hand, the incidence of brain metastasis
was higher in the group with normal LDH levels (29 vs. 14%).
Regarding number of metastatic sites there was a trend
toward more metastatic sites in patients with severe
elevated LDH levels showing 2 metastatic sites in 34 vs. 26%
and 4 or more metastatic sites in 5 vs. 1% (Table 5).
There was no influence on treatment as 98% of all
patients with SCLC ED received platinum based therapies
with etoposide being the most commonly used second
compound (90%).
In the group with normal LDH levels, 65.5% had PR, 6.9%
CR, resulting in 72.4% RR. 12.6% had PD as result of first line
treatment. 10 pts were censored. The remaining 75 pts
presented a median survival of 12.3 months.
Of 154 pts with elevated LDH levels, PR was seen in
63.9%, CR in 2.6%, yielding a RR of 66.5%. PD resulted of
first line treatment in 23.1%. Only 6 (3%) were still alive at
time of data analysis. Median survival was 9.6 months in this
group. As in LD SCLC, there was no statistically significantFigure 1 Median survival in LD SCLC with normal versus
elevated LDH levels.
Figure 2 Median survival in LD SCLC with different LDH level
subgroups.
Table 5 Correlation of localization of metastases and
number of metastatic sites with different LDH-levels.
LDH-level (U/l) 225 >225e300 >300
CNS 29% 25% 14%
Liver 25% 40% 58%
Adrenal glands 12% 7% 16%
Bone 20% 30% 34%
Lung 23% 25% 16%
Pleura 11% 20% 13%
Other 2% 10% 11%
Number of metastatic sites
1 64% 60% 49%
2 26% 26% 34%
3 9% 10% 12%
4 or more 1% 4% 5%
Table 6 LDH serum levels and treatment response in
extensive disease SCLC.
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categories (Table 6).
There was no difference in PS between the patients with
normal vs. elevated LDH levels (1.16 vs. 1.29). A slightly
higher age was detected in the cohort with elevated LDH
levels (62 vs. 65 years).
After inclusion of all censored events into statistical
analysis, a significant reduction in median survival was
detected in the group with elevated LDH levels compared
with cases with LDH level below upper limit normal
(Table 7).
Patients with LDH levels above 300 U/l had a signifi-
cantly shorter survival (7.0 months) (Table 8, Figs. 3 and 4).
Multivariate Cox regression analyses revealed LDH levels
to be an independent predictor of mortality after adjust-
ment for age and Performance Status also in ED SCLC
(Hazard Ratio 1.001, p Z 0.002) (Table 9).
Thus, statistical evaluation strongly confirmed an inde-
pendent prognostic value for LDH in both limited and
extensive stage SCLC.
Discussion
The present data confirm the significance of lactate dehy-
drogenase as a strong independent pre-treatment factor in
small cell lung cancer in a large unselected contemporary
patient population with limited and extensive stage disease
treated at our institution between 2004 and 2009. We hadTable 4 multivariate Cox regression analyses in LD SCLC.
Variable HR (CI 95%) p-value
Age 1.009 (0.989e1.030) 0.363
LDH 1.003 (1.000e1.005) 0.017
Performance Status 1.965 (1.062e3.635) 0.031data available on all patients. 48 cases were censored, but
included into statistical analyses. In contrast to other pub-
lished studies, wewere able to retrieve LDH levels for almost
all (99.5%) patients, and cases with LD and ED SCLC were
separately assessed. Elevated LDH levels are known to
correlate with inflammation and tumor necrosis, thus
reflecting tumor activity. Mayor confounding factors which
might have led to elevated LDH levels were largely excluded
at base line.
In patients with limited disease SCLC, response rate was
not altered by LDH levels. In patients with elevated LDH
levels (>225 U/l), survival was significantly reduced. When
we further divided these cases into two groups (LDH
225e300 U/l and <300 U/l) there was a considerably
shorter median survival in the latter group. However, there
were only 25 cases of which 7 were censored. Thus,
statistical significance was not reached. This is also visible
in Fig. 2 where the line representing LDH levels above
300 U/l ends at 0.2.
The median survival of patients with LD SCLC and
elevated LDH levels beyond 300 U/l was actually similar
to the median survival in patients with ED SCLC. It might
be true that markedly elevated LDH levels are suggestive
of higher tumor burden or tumor activity even though
distant metastasis cannot be detected by standard
staging procedures. We looked at tumor size in this
patient group in order to possibly detect bulky thoracic
disease as cause for higher tumor burden and thus
elevated LDH levels. In 19 of 25 patients, CT-scans wereResponse LDH <225 U/l
n Z 87
LDH >225 U/l
n Z 154
P-Value *
Complete response 6.9% 2.6% .106
Partial response 65.5% 63.9% .797
Response rate 72.4% 66.5% .338
Stable disease 14.9% 10.3% .288
Progressive disease 12.6% 23.2% .046
*Chi-square test.
Table 7 Log-rank test for median survival in ED SCLC with
normal versus elevated LDH serum levels.
LDH level (U/l) Median Survival (months) p-value
LDH  225 12.0 (10.7e13.3) Ref.
LDH > 225 8.0 (6.7e9.3) .004
Figure 3 Median survival in ED SCLC with normal versus
elevated LDH levels.
LDH in small cell lung cancer 1941obtainable. Mean tumor size was 6.1 cm, thus there was
no tale of especially big or bulky lesions in these
patients.
Our patients with ED SCLC showed typical frequency
and localization of metastases. We noted a correlation
between severe elevated LDH levels (>300 U/l) and
a higher incidence of liver metastases (58 vs. 25%) and
bone metastases (34 vs. 20%) compared to patients with
normal LDH levels. In addition, there was a trend toward
more metastatic sites in patients with severe elevated
LDH levels. Both findings might play a role in the design of
future studies on new chemotherapeutic agents in the
treatment of small cell lung cancer. A statistically signif-
icant increased rate of primary progressive disease as
result on first line therapy (12.6 versus 23.2%, p Z 0.046)
was seen in the cases with elevated LDH levels. In patients
with ED SCLC and normal LDH serum levels a trend toward
higher response rates was detected (p Z 0.338). Median
survival was significantly reduced in patients with
elevated LDH levels. After further differentiation of the
cases, the group with strongly elevated levels (above
300 U/l) showed an even more pronounced effect on
survival. These patients had a median survival of only
7.0 months compared to 12.0 months with normal LDH
serum levels.
Determination of LDH levels is advantageous as the
method is readily available in routine laboratory panels;
actually it is part of most routine laboratory assessment
panels in patients with suspected thoracic cancer. The test
is inexpensive and standardized.
In earlier reports a certain degree of bone marrow
involvement of 10e16% was seen.26,27 In another publica-
tion only two of 110 patients with normal LDH levels had
bone marrow involvement.28 The question arises whether
one might omit bone marrow sampling in patients with
normal LDH levels.
Besides LDH levels, disease stage and performance were
the two other variables which also were statistically proven
to be significant as predictive factors. We additionally
analyzed whether gender might be another predictive
factor. However, in our comprehensive patient population,
gender did not reach statistical significance as prognostic
marker.Table 8 log-rank test for median survival in ED SCLC with
different LDH serum levels.
LDH level (U/l) Median Survival (months) p-value
LDH  225 12.0 (10.7e13.3) Ref.
LDH > 225e<300 11.0 (9.1e12.9) 0.360
LDH > 300 7.0 (6.0e7.9) <0.001In conclusion, LDH is an easily obtainable strong pre-
treatment predictor of outcome in patients with limited
and extensive stage small cell lung cancer using a threshold
of 225 U/l as upper limit normal. The independent level of
LDH was confirmed by statistical adjustment for the two
other most important predictive markers: extend of disease
and clinical performance status. There is a trend toward
even more reduced overall survival in LD SCLC with LDH
levels above 300 U/l. In patients with ED SCLC with such
elevated LDH levels, median survival was significantly
shorter.
LDH should still be measured in every patient with small
cell lung cancer and seriously taken into consideration
when assessing prognosis and treatment options in the
individual patient.Figure 4 Median survival in ED SCLC with different LDH level
subgroups.
Table 9 multivariate Cox regression analyses in ED SCLC.
Variable HR (CI 95%) p-value
Age 1.000 (0.987e1.024) 0.564
LDH 1.000 (1.000e1.001) 0.002
Performance Status 2.033 (1.452e2.845) 0.000
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